Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
As the benefits of the GLP-1 receptor agonists with type 2 diabetes, obesity, and cardiovascular health have become widely known, research has accelerated, and potential new opportunities have risen to utilize GLP-1s to treat other conditions: 1
The cost savings are minimal compared to the risks
For a person starting at 248 pounds (the average baseline weight in the trial), that works out to a loss of roughly 71 pounds on the higher dose
Regulatory uncertainty limits its medical positioning, currently placing it in the grey zone of experimental peptides These limitations make clinical endorsement premature, especially in regulated health systems or for medical-grade use
US$ 25.19
US$ 23.36
US$ 28.07
